Esophageal Disease Articles & Analysis: Older
15 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including ...
Unsedated TNE can be used to evaluate and diagnose a wide range of upper GI conditions that may require frequent monitoring including eosinophilic esophagitis (EoE), dysphagia, celiac disease, gastroesophageal reflux disease, Barrett’s esophagus, malabsorption, and abdominal pain. ...
ByEvoEndo
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease ...
“We are extremely pleased that The Medicine Maker is reporting on how EsoCap’s unique and innovative topical drug delivery system offers new treatment options for diseases of the esophagus,” said Isabelle Racamier, EsoCap AG CEO. “The interview is a great opportunity to highlight the challenges of esophageal disease and ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced the publication of paper establishing the basis for using its product to ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced it has hired David Green as its Chief Executive Officer and appointed Mr. ...
“The start of our ACESO trial marks an important milestone in the development of our unique application platform to treat esophageal diseases. The EsoCap system has proven fully functional and was shown to be well accepted in a previous trial conducted in healthy volunteers. ...
In contrast to tablets, capsules or viscous fluids, which are known for short esophageal transit times, for the first time the EsoCap system ensures a targeted and long-lasting drug delivery in the esophagus. ...
The development of novel and improved treatment options for patients is EsoCap’s mission and its lead candidate ESO-101 has the potential to provide significant clinical benefits to EoE patients. “Eosinophilic esophagitis is a rare and chronic disease with very limited treatment options. Esocap supports the first EoE awareness campaign for this ...
AnX Robotica Corporation, (www.anxrobotics.com), the developer and manufacturer of the NaviCam Magnetically Controlled Capsule Endoscopy (MCCE) System, is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for Magnetically controlled capsule endoscopy, which can help clinicians to diagnose and treat patients with ...
The patent is directed at the smart application technology enabling specific sitedirected treatment of several diseases of the esophagus. “Issue of the U.S. patent is a major milestone confirming the novelty of EsoCap’s proprietary technology”, commented Isabelle Racamier, EsoCap AG CEO. ...
Goode has extensive research, development, regulatory and early commercialization experience with active implantable devices and bioelectronic therapies for heart failure, metabolic disease and esophageal reflux disease (GERD). Prior to joining Orchestra BioMed, he held several leadership positions at EndoStim including vice president R&D, ...